{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:35:46Z","timestamp":1762868146862,"version":"3.37.3"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Prototype Development Research Grant Scheme","award":["PRGS\/2\/2015\/ SKK10\/AIMST\/02\/1"],"award-info":[{"award-number":["PRGS\/2\/2015\/ SKK10\/AIMST\/02\/1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Cholera, an acute watery diarrhoeal disease caused by <jats:italic>Vibrio cholerae<\/jats:italic> serogroup O1 and O139 across the continents. Replacing the existing WHO licensed killed multiple-dose oral cholera vaccines that demand \u2018cold chain supply\u2019 at 2\u20138\u2009\u00b0C with a live, single-dose and cold chain-free vaccine would relieve the significant bottlenecks and cost determinants in cholera vaccination campaigns. In this direction, a prototype cold chain-free live attenuated cholera vaccine formulation (LACV) was developed against the toxigenic wild-type (WT) <jats:italic>V. cholerae<\/jats:italic> O139 serogroup. LACV was found stable and retained its viability (5\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\u2009CFU\/mL), purity and potency at room temperature (25\u2009\u00b0C\u2009\u00b1\u20092\u2009\u00b0C, and 60%\u2009\u00b1\u20095% relative humidity) for 140\u2009days in contrast to all the existing WHO licensed cold-chain supply (2\u20138\u2009\u00b0C) dependent killed oral cholera vaccines.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The LACV was evaluated for its colonization potential, reactogenicity, immunogenicity and protective efficacy in animal models after its storage at room temperature for 140\u2009days. In suckling mice colonization assay, the LACV recorded the highest recovery of (7.2\u2009\u00d7\u200910<jats:sup>7<\/jats:sup>\u2009CFU\/mL) compared to those of unformulated VCUSM14P (5.6\u2009\u00d7\u200910<jats:sup>7<\/jats:sup>\u2009CFU\/mL) and the WT O139 strain (3.5\u2009\u00d7\u200910<jats:sup>7<\/jats:sup>\u2009CFU\/mL). The LACV showed no reactogenicity even at an inoculation dose of 10<jats:sup>4<\/jats:sup>\u201310<jats:sup>6<\/jats:sup>\u2009CFU\/mL in a rabbit ileal loop model. The rabbits vaccinated with the LACV or unformulated VCUSM14P survived a challenge with WT O139 and showed no signs of diarrhoea or death in the reversible intestinal tie adult rabbit diarrhoea (RITARD) model. Vaccinated rabbits recorded a 275-fold increase in anti-CT IgG and a 15-fold increase in anti-CT IgA antibodies compared to those of rabbits vaccinated with unformulated VCUSM14P. Vibriocidal antibodies were increased by 31-fold with the LACV and 14-fold with unformulated VCUSM14P.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The vaccine formulation mimics a natural infection, is non-reactogenic and highly immunogenic in vivo and protects animals from lethal wild-type <jats:italic>V. cholerae<\/jats:italic> O139 challenge. The single dose LACV formulation was found to be stable at room temperature (25\u2009\u00b1\u20092\u2009\u00b0C) for 140\u2009days and it would result in significant cost savings during mass cholera vaccination campaigns.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12865-020-00360-1","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T13:02:49Z","timestamp":1590411769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140\u2009days"],"prefix":"10.1186","volume":"21","author":[{"given":"Tew Hui","family":"Xian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurunathan","family":"Sinniah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Yean","family":"Yean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkateskumar","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Baidi","family":"Bahari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manickam","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5092-3941","authenticated-orcid":false,"given":"Guruswamy","family":"Prabhakaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"360_CR1","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1016\/S0140-6736(12)60436-X","volume":"379","author":"JB Harris","year":"2012","unstructured":"Harris JB, LaRocque RC, Qadri F, et al. Cholera. Lancet. 2012;379:2466\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(12)60436-X.","journal-title":"Lancet"},{"issue":"6","key":"360_CR2","doi-asserted-by":"publisher","first-page":"e0003832","DOI":"10.1371\/journal.pntd.0003832","volume":"9","author":"M Ali","year":"2015","unstructured":"Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832. https:\/\/doi.org\/10.1371\/journal.pntd.0003832.","journal-title":"PLoS Negl Trop Dis"},{"issue":"Suppl 1","key":"360_CR3","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/S0163-4453(17)30194-9","volume":"74","author":"HG Davies","year":"2017","unstructured":"Davies HG, Bowman C, Luby SP. Cholera - management and prevention. J Inf Secur. 2017;74(Suppl 1):S66\u201373. https:\/\/doi.org\/10.1016\/S0163-4453(17)30194-9.","journal-title":"J Inf Secur"},{"key":"360_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1086\/313951","volume":"31","author":"ET Ryan","year":"2000","unstructured":"Ryan ET, Calderwood SB. Cholera vaccines. Clin Infect Dis. 2000;31:561\u20135. https:\/\/doi.org\/10.1086\/313951.","journal-title":"Clin Infect Dis"},{"key":"360_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1086\/341206","volume":"186","author":"IM Longini","year":"2002","unstructured":"Longini IM, Yunus M, Zaman K, et al. Epidemic and endemic cholera trends over a 33-year period in Bangladesh. J Infect Dis. 2002;186:246\u201351. https:\/\/doi.org\/10.1086\/341206.","journal-title":"J Infect Dis"},{"key":"360_CR6","doi-asserted-by":"publisher","first-page":"E7730","DOI":"10.1073\/pnas.1608732113","volume":"113","author":"D Hu","year":"2016","unstructured":"Hu D, Liu B, Feng L, et al. Origins of the current seventh cholera pandemic. Proc Natl Acad Sci U S A. 2016;113:E7730\u20139. https:\/\/doi.org\/10.1073\/pnas.1608732113.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"360_CR7","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1371\/journal.ppat.0030081","volume":"3","author":"M Blokesch","year":"2007","unstructured":"Blokesch M, Schoolnik GK. Serogroup conversion of Vibrio cholerae in aquatic reservoirs. PLoS Pathog. 2007;3:e81. https:\/\/doi.org\/10.1371\/journal.ppat.0030081.","journal-title":"PLoS Pathog"},{"key":"360_CR8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/nature10392","volume":"477","author":"A Mutreja","year":"2011","unstructured":"Mutreja A, Kim DW, Thomson NR, et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature. 2011;477:462\u20135. https:\/\/doi.org\/10.1038\/nature10392.","journal-title":"Nature"},{"key":"360_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.tim.2009.10.003","volume":"18","author":"A Safa","year":"2010","unstructured":"Safa A, Nair GB, Kong RYC. Evolution of new variants of Vibrio cholerae O1. Trends Microbiol. 2010;18:46\u201354. https:\/\/doi.org\/10.1016\/j.tim.2009.10.003.","journal-title":"Trends Microbiol"},{"key":"360_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0264-410X(93)90019-T","volume":"11","author":"MM Levine","year":"1993","unstructured":"Levine MM, Kaper JB. Live oral vaccines against cholera: an update. Vaccine. 1993;11:207\u201312. https:\/\/doi.org\/10.1016\/0264-410X(93)90019-T.","journal-title":"Vaccine"},{"key":"360_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/infdis\/169.1.230","volume":"169","author":"MJ Albert","year":"1994","unstructured":"Albert MJ, Alam K, Ansaruzzaman M, et al. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR. J Infect Dis. 1994;169:230\u20131.","journal-title":"J Infect Dis"},{"key":"360_CR12","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1128\/IAI.65.9.3571-3576.1997","volume":"65","author":"F Qadri","year":"1997","unstructured":"Qadri F, Wenner\u00e5s C, Albert MJ, et al. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect Immun. 1997;65:3571\u20136.","journal-title":"Infect Immun"},{"key":"360_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1093\/infdis\/jir416","volume":"204","author":"M Ali","year":"2011","unstructured":"Ali M, Emch M, Park JK, et al. Natural cholera infection-derived immunity in an endemic setting. J Infect Dis. 2011;204:912\u20138. https:\/\/doi.org\/10.1093\/infdis\/jir416.","journal-title":"J Infect Dis"},{"key":"360_CR14","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3892\/mmr.2014.2065","volume":"9","author":"C Cheng","year":"2014","unstructured":"Cheng C, Zhou Y, Kan B, et al. Construction and characterization of a Vibrio cholerae serogroup O139 vaccine candidate by genetic engineering. Mol Med Rep. 2014;9:2239\u201344. https:\/\/doi.org\/10.3892\/mmr.2014.2065.","journal-title":"Mol Med Rep"},{"key":"360_CR15","doi-asserted-by":"publisher","first-page":"e1001867","DOI":"10.1371\/journal.pmed.1001867","volume":"12","author":"AS Azman","year":"2015","unstructured":"Azman AS, Luquero FJ, Ciglenecki I, et al. The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: a modeling study. PLoS Med. 2015;12:e1001867. https:\/\/doi.org\/10.1371\/journal.pmed.1001867.","journal-title":"PLoS Med"},{"issue":"12","key":"360_CR16","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1093\/cid\/cix1039","volume":"66","author":"Anna Lena Lopez","year":"2017","unstructured":"Lopez AL, Deen J, Azman AS, et al. Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review and metaanalysis. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/cix1039.","journal-title":"Clinical Infectious Diseases"},{"key":"360_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1586\/14760584.5.4.483","volume":"5","author":"ET Ryan","year":"2006","unstructured":"Ryan ET, Calderwood SB, Qadri F. Live attenuated oral cholera vaccines. Expert Rev Vaccines. 2006;5:483\u201394. https:\/\/doi.org\/10.1586\/14760584.5.4.483.","journal-title":"Expert Rev Vaccines"},{"key":"360_CR18","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1586\/erv.09.137","volume":"8","author":"MI Chowdhury","year":"2009","unstructured":"Chowdhury MI, Sheikh A, Qadri F. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009. Expert Rev Vaccines. 2009;8:1643\u201352. https:\/\/doi.org\/10.1586\/erv.09.137.","journal-title":"Expert Rev Vaccines"},{"key":"360_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.7883\/yoken.67.145","volume":"67","author":"T Mahapatra","year":"2014","unstructured":"Mahapatra T, Mahapatra S, Babu GR, et al. Cholera outbreaks in South and Southeast Asia: descriptive analysis, 2003-2012. Jpn J Infect Dis. 2014;67:145\u201356.","journal-title":"Jpn J Infect Dis"},{"key":"360_CR20","volume-title":"Cholera","author":"WHO","year":"2019","unstructured":"WHO (2019) Cholera. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cholera. Accessed 28 Jan 2019."},{"key":"360_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.vaccine.2015.10.112","volume":"34","author":"CR Phares","year":"2016","unstructured":"Phares CR, Date K, Travers P, et al. Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand. Vaccine. 2016;34:128\u201333. https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.112.","journal-title":"Vaccine"},{"key":"360_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/trstmh\/tru153","volume":"108","author":"MI Porta","year":"2014","unstructured":"Porta MI, Lenglet A, de Weerdt S, et al. Feasibility of a preventive mass vaccination campaign with two doses of oral cholera vaccine during a humanitarian emergency in South Sudan. Trans R Soc Trop Med Hyg. 2014;108:810\u20135. https:\/\/doi.org\/10.1093\/trstmh\/tru153.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"360_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2471\/BLT.11.030511","volume":"89","author":"G Humphreys","year":"2011","unstructured":"Humphreys G. Vaccination: rattling the supply chain. Bull World Health Organ. 2011;89:324\u20135. https:\/\/doi.org\/10.2471\/BLT.11.030511.","journal-title":"Bull World Health Organ"},{"issue":"Suppl 2","key":"360_CR24","doi-asserted-by":"publisher","first-page":"B73","DOI":"10.1016\/j.vaccine.2012.11.036","volume":"31","author":"M Zaffran","year":"2013","unstructured":"Zaffran M, Vandelaer J, Kristensen D, et al. The imperative for stronger vaccine supply and logistics systems. Vaccine. 2013;31(Suppl 2):B73\u201380. https:\/\/doi.org\/10.1016\/j.vaccine.2012.11.036.","journal-title":"Vaccine"},{"key":"360_CR25","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1016\/j.vaccine.2015.05.071","volume":"33","author":"CL Karp","year":"2015","unstructured":"Karp CL, Lans D, Esparza J, et al. Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries. Vaccine. 2015;33:3471\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.071.","journal-title":"Vaccine"},{"key":"360_CR26","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.vaccine.2003.12.033","volume":"22","author":"J-F Viret","year":"2004","unstructured":"Viret J-F, Dietrich G, Favre D. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine. 2004;22:2457\u201369. https:\/\/doi.org\/10.1016\/j.vaccine.2003.12.033.","journal-title":"Vaccine"},{"key":"360_CR27","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1073\/pnas.0915164107","volume":"107","author":"H Rui","year":"2010","unstructured":"Rui H, Ritchie JM, Bronson RT, et al. Reactogenicity of live-attenuated Vibrio cholerae vaccines is dependent on flagellins. Proc Natl Acad Sci U S A. 2010;107:4359\u201364. https:\/\/doi.org\/10.1073\/pnas.0915164107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"360_CR28","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1128\/IAI.62.4.1480-1483.1994","volume":"62","author":"JB Kaper","year":"1994","unstructured":"Kaper JB, Michalski J, Ketley JM, Levine MM. Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR. Infect Immun. 1994;62:1480\u20133.","journal-title":"Infect Immun"},{"key":"360_CR29","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/cid\/ciw145","volume":"62","author":"WH Chen","year":"2016","unstructured":"Chen WH, Cohen MB, Kirkpatrick BD, et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis. 2016;62:1329\u201335. https:\/\/doi.org\/10.1093\/cid\/ciw145.","journal-title":"Clin Infect Dis"},{"key":"360_CR30","doi-asserted-by":"publisher","first-page":"e99381","DOI":"10.1371\/journal.pone.0099381","volume":"9","author":"S Kanungo","year":"2014","unstructured":"Kanungo S, Sen B, Ramamurthy T, et al. Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India. PLoS ONE. 2014;9:e99381. https:\/\/doi.org\/10.1371\/journal.pone.0099381.","journal-title":"PLoS ONE"},{"key":"360_CR31","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/infdis\/172.4.1126","volume":"172","author":"JR Kenner","year":"1995","unstructured":"Kenner JR, Coster TS, Taylor DN, et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis. 1995;172:1126\u20139.","journal-title":"J Infect Dis"},{"key":"360_CR32","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.1128\/IAI.71.10.5498-5504.2003","volume":"71","author":"W Liang","year":"2003","unstructured":"Liang W, Wang S, Yu F, et al. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun. 2003;71:5498\u2013504.","journal-title":"Infect Immun"},{"key":"360_CR33","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1128\/IAI.73.5.3018-3024.2005","volume":"73","author":"L Garc\u00eda","year":"2005","unstructured":"Garc\u00eda L, Jidy MD, Garc\u00eda H, et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun. 2005;73:3018\u201324. https:\/\/doi.org\/10.1128\/IAI.73.5.3018-3024.2005.","journal-title":"Infect Immun"},{"key":"360_CR34","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1016\/j.vaccine.2005.07.015","volume":"24","author":"A Talavera","year":"2006","unstructured":"Talavera A, A\u00f1o G, Garc\u00eda H, et al. Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638. Vaccine. 2006;24:3746\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2005.07.015.","journal-title":"Vaccine"},{"key":"360_CR35","first-page":"59","volume":"53","author":"MM Levine","year":"1983","unstructured":"Levine MM, Black RE, Clements ML, et al. Texas star-SR: attenuated \u201cVibrio cholerae\u201d oral vaccine candidate. Dev Biol Stand. 1983;53:59\u201365.","journal-title":"Dev Biol Stand"},{"key":"360_CR36","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1016\/j.vaccine.2012.02.012","volume":"30","author":"HF Zamri","year":"2012","unstructured":"Zamri HF, Shamsudin MN, Rahim RA, Neela V. Oral vaccination with Lactococcus lactis expressing the Vibrio cholerae Wzm protein to enhance mucosal and systemic immunity. Vaccine. 2012;30:3231\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2012.02.012.","journal-title":"Vaccine"},{"key":"360_CR37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/infdis\/172.3.883","volume":"172","author":"CO Tacket","year":"1995","unstructured":"Tacket CO, Losonsky G, Nataro JP, et al. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis. 1995;172:883\u20136.","journal-title":"J Infect Dis"},{"key":"360_CR38","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(95)90698-3","volume":"345","author":"TS Coster","year":"1995","unstructured":"Coster TS, Killeen KP, Waldor MK, et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet. 1995;345:949\u201352.","journal-title":"Lancet"},{"key":"360_CR39","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.micinf.2012.04.004","volume":"14","author":"T Led\u00f3n","year":"2012","unstructured":"Led\u00f3n T, Ferr\u00e1n B, P\u00e9rez C, et al. TLP01, an mshA mutant of Vibrio cholerae O139 as vaccine candidate against cholera. Microbes Infect. 2012;14:968\u201378. https:\/\/doi.org\/10.1016\/j.micinf.2012.04.004.","journal-title":"Microbes Infect"},{"key":"360_CR40","doi-asserted-by":"publisher","first-page":"949","DOI":"10.5555\/uri:pii:S0140673695906983","volume":"345","author":"KP Killeen","year":"1995","unstructured":"Killeen KP, Beattie DT, Spriggs DR, et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae 0139 vaccine prototype. Lancet. 1995;345:949\u201352. https:\/\/doi.org\/10.5555\/uri:pii:S0140673695906983.","journal-title":"Lancet"},{"key":"360_CR41","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/S0264-410X(02)00412-7","volume":"21","author":"T Led\u00f3n","year":"2003","unstructured":"Led\u00f3n T, Valle E, Valmaseda T, et al. Construction and characterisation of O139 cholera vaccine candidates. Vaccine. 2003;21:1282\u201391.","journal-title":"Vaccine"},{"key":"360_CR42","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1016\/j.vaccine.2005.07.016","volume":"24","author":"M Ravichandran","year":"2006","unstructured":"Ravichandran M, Ali SA, Rashid NHA, et al. Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutation. Vaccine. 2006;24:3750\u201361. https:\/\/doi.org\/10.1016\/j.vaccine.2005.07.016.","journal-title":"Vaccine"},{"key":"360_CR43","volume-title":"Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof","author":"M Ravichandran","year":"2008","unstructured":"Ravichandran M, Ali SA, Rashid NHA, et al (2008) Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof."},{"key":"360_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.micpath.2010.06.001","volume":"49","author":"M Chan","year":"2010","unstructured":"Chan M, Cheong TG, Kurunathan S, et al. Construction and characterization of an auxotrophic ctxA mutant of O139 Vibrio cholerae. Microb Pathog. 2010;49:211\u20136. https:\/\/doi.org\/10.1016\/j.micpath.2010.06.001.","journal-title":"Microb Pathog"},{"key":"360_CR45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.vaccine.2018.12.027","volume":"37","author":"TH Xian","year":"2019","unstructured":"Xian TH, Parasuraman S, Sinniah K, et al. Repeated dose toxicity evaluation of a cold chain-free, live, attenuated oral cholera vaccine in Sprague Dawley rats. Vaccine. 2019;37:711\u201320. https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.027.","journal-title":"Vaccine"},{"key":"360_CR46","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1128\/IAI.41.2.735-741.1983","volume":"41","author":"WC Cray","year":"1983","unstructured":"Cray WC, Tokunaga E, Pierce NF. Successful colonization and immunization of adult rabbits by oral inoculation with Vibrio cholerae O1. Infect Immun. 1983;41:735\u201341.","journal-title":"Infect Immun"},{"key":"360_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1128\/CMR.8.1.48","volume":"8","author":"JB Kaper","year":"1995","unstructured":"Kaper JB, Morris JG, Levine MM. Cholera. Clin Microbiol Rev. 1995;8:48\u201386.","journal-title":"Clin Microbiol Rev"},{"key":"360_CR48","doi-asserted-by":"publisher","first-page":"e1004787","DOI":"10.1371\/journal.ppat.1004787","volume":"11","author":"S Almagro-Moreno","year":"2015","unstructured":"Almagro-Moreno S, Pruss K, Taylor RK. Intestinal colonization dynamics of Vibrio cholerae. PLoS Pathog. 2015;11:e1004787. https:\/\/doi.org\/10.1371\/journal.ppat.1004787.","journal-title":"PLoS Pathog"},{"key":"360_CR49","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1371\/journal.ppat.0030147","volume":"3","author":"P Schmid-Hempel","year":"2007","unstructured":"Schmid-Hempel P, Frank SA. Pathogenesis, virulence, and infective dose. PLoS Pathog. 2007;3:1372\u20133. https:\/\/doi.org\/10.1371\/journal.ppat.0030147.","journal-title":"PLoS Pathog"},{"key":"360_CR50","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S1534-5807(03)00295-8","volume":"5","author":"J Zhu","year":"2003","unstructured":"Zhu J, Mekalanos JJ. Quorum sensing-dependent biofilms enhance colonization in Vibrio cholerae. Dev Cell. 2003;5:647\u201356.","journal-title":"Dev Cell"},{"key":"360_CR51","doi-asserted-by":"publisher","first-page":"e81817","DOI":"10.1371\/journal.pone.0081817","volume":"9","author":"C Murugaiah","year":"2014","unstructured":"Murugaiah C, Nik Mohd Noor NZ, Mustafa S, et al. Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine. PLoS One. 2014;9:e81817. https:\/\/doi.org\/10.1371\/journal.pone.0081817.","journal-title":"PLoS One"},{"key":"360_CR52","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.vaccine.2017.12.062","volume":"36","author":"JM McCarty","year":"2018","unstructured":"McCarty JM, Lock MD, Hunt KM, et al. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. Vaccine. 2018;36:833\u201340. https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.062.","journal-title":"Vaccine"},{"key":"360_CR53","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1128\/IAI.74.5.2937-2946.2006","volume":"74","author":"A Ghosh","year":"2006","unstructured":"Ghosh A, Saha DR, Hoque KM, et al. Enterotoxigenicity of mature 45-kilodalton and processed 35-kilodalton forms of hemagglutinin protease purified from a cholera toxin gene-negative Vibrio cholerae non-O1, non-O139 strain. Infect Immun. 2006;74:2937\u201346. https:\/\/doi.org\/10.1128\/IAI.74.5.2937-2946.2006.","journal-title":"Infect Immun"},{"key":"360_CR54","doi-asserted-by":"publisher","first-page":"e76200","DOI":"10.1371\/journal.pone.0076200","volume":"8","author":"N Rajpara","year":"2013","unstructured":"Rajpara N, Vinothkumar K, Mohanty P, et al. Synergistic effect of various virulence factors leading to high toxicity of environmental V. cholerae non-O1\/ non-O139 isolates lacking ctx gene : comparative study with clinical strains. PLoS One. 2013;8:e76200. https:\/\/doi.org\/10.1371\/journal.pone.0076200.","journal-title":"PLoS One"},{"key":"360_CR55","doi-asserted-by":"publisher","first-page":"559","DOI":"10.14670\/HH-24.559","volume":"24","author":"A Amin","year":"2009","unstructured":"Amin A, Ali A, Kurunathan S, et al. Comparison of histopathological features of Vibrio cholerae O1 El Tor and O139 Bengal infections in rabbit intestinal mucosa. Histol Histopathol. 2009;24:559\u201365. https:\/\/doi.org\/10.14670\/HH-24.559.","journal-title":"Histol Histopathol"},{"key":"360_CR56","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1016\/S0264-410X(03)00388-8","volume":"21","author":"FO Eko","year":"2003","unstructured":"Eko FO, Schukovskaya T, Lotzmanova EY, et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine. 2003;21:3663\u201374.","journal-title":"Vaccine"},{"key":"360_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1574-695X.2010.00692.x","volume":"60","author":"N Roy","year":"2010","unstructured":"Roy N, Barman S, Ghosh A, et al. Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model. FEMS Immunol Med Microbiol. 2010;60:18\u201327. https:\/\/doi.org\/10.1111\/j.1574-695X.2010.00692.x.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"360_CR58","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.1016\/j.vaccine.2007.02.043","volume":"25","author":"M Yan","year":"2007","unstructured":"Yan M, Liu G, Diao B, et al. A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET phi infection. Vaccine. 2007;25:4046\u201355. https:\/\/doi.org\/10.1016\/j.vaccine.2007.02.043.","journal-title":"Vaccine"},{"key":"360_CR59","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1016\/j.vaccine.2003.12.004","volume":"22","author":"DES Stewart-Tull","year":"2004","unstructured":"Stewart-Tull DES, Lucas C, Bleakley CR. Experimental immunisation and protection of Guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase. Vaccine. 2004;22:2137\u201345. https:\/\/doi.org\/10.1016\/j.vaccine.2003.12.004.","journal-title":"Vaccine"},{"key":"360_CR60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1574-695X.2009.00563.x","volume":"56","author":"J Kundu","year":"2009","unstructured":"Kundu J, Mazumder R, Srivastava R, Srivastava BS. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge. FEMS Immunol Med Microbiol. 2009;56:179\u201384. https:\/\/doi.org\/10.1111\/j.1574-695X.2009.00563.x.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"360_CR61","doi-asserted-by":"publisher","first-page":"e57269","DOI":"10.1371\/journal.pone.0057269","volume":"8","author":"GA Price","year":"2013","unstructured":"Price GA, McFann K, Holmes RK. Immunization with cholera toxin B subunit induces high-level protection in the suckling mouse model of cholera. PLoS One. 2013;8:e57269. https:\/\/doi.org\/10.1371\/journal.pone.0057269.","journal-title":"PLoS One"},{"key":"360_CR62","doi-asserted-by":"publisher","first-page":"e2323","DOI":"10.1371\/journal.pone.0002323","volume":"3","author":"D Mahalanabis","year":"2008","unstructured":"Mahalanabis D, Lopez AL, Sur D, et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One. 2008;3:e2323. https:\/\/doi.org\/10.1371\/journal.pone.0002323.","journal-title":"PLoS One"},{"key":"360_CR63","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.4161\/hv.29199","volume":"10","author":"SN Desai","year":"2014","unstructured":"Desai SN, Cravioto A, Sur D, Kanungo S. Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines. Hum Vaccin Immunother. 2014;10:1457\u201365. https:\/\/doi.org\/10.4161\/hv.29199.","journal-title":"Hum Vaccin Immunother"},{"key":"360_CR64","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7774\/cevr.2018.7.2.104","volume":"7","author":"EY Lee","year":"2018","unstructured":"Lee EY, Lee S, Rho S, et al. Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model. Clin Exp Vaccine Res. 2018;7:104\u201310. https:\/\/doi.org\/10.7774\/cevr.2018.7.2.104.","journal-title":"Clin Exp Vaccine Res"},{"key":"360_CR65","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0966-842X(00)01721-2","volume":"8","author":"KE Klose","year":"2000","unstructured":"Klose KE. The suckling mouse model of cholera. Trends Microbiol. 2000;8:189\u201391. https:\/\/doi.org\/10.1016\/S0966-842X(00)01721-2.","journal-title":"Trends Microbiol"},{"key":"360_CR66","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1128\/IAI.73.10.6674-6679.2005","volume":"73","author":"A Alam","year":"2005","unstructured":"Alam A, Larocque RC, Harris JB, et al. Hyperinfectivity of human-passaged Vibrio cholerae can be modeled by growth in the infant mouse. Infect Immun. 2005;73:6674\u20139. https:\/\/doi.org\/10.1128\/IAI.73.10.6674-6679.2005.","journal-title":"Infect Immun"},{"key":"360_CR67","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1128\/IAI.00532-08","volume":"76","author":"S Schild","year":"2008","unstructured":"Schild S, Nelson EJ, Camilli A. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun. 2008;76:4554\u201363. https:\/\/doi.org\/10.1128\/IAI.00532-08.","journal-title":"Infect Immun"},{"key":"360_CR68","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-3-642-01846-6_2","volume":"337","author":"JM Ritchie","year":"2009","unstructured":"Ritchie JM, Waldor MK. Vibrio cholerae interactions with the gastrointestinal tract: lessons from animal studies. Curr Top Microbiol Immunol. 2009;337:37\u201359. https:\/\/doi.org\/10.1007\/978-3-642-01846-6_2.","journal-title":"Curr Top Microbiol Immunol"},{"key":"360_CR69","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/infdis\/jir756","volume":"205","author":"AL Bishop","year":"2012","unstructured":"Bishop AL, Tarique AA, Patimalla B, et al. Immunization of mice with Vibrio cholerae outer-membrane vesicles protects against hyperinfectious challenge and blocks transmission. J Infect Dis. 2012;205:412\u201321. https:\/\/doi.org\/10.1093\/infdis\/jir756.","journal-title":"J Infect Dis"},{"key":"360_CR70","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1128\/IAI.67.8.3733-3739.1999","volume":"67","author":"MJ Angelichio","year":"1999","unstructured":"Angelichio MJ, Spector J, Waldor MK, Camilli A. Vibrio cholerae intestinal population dynamics in the suckling mouse model of infection. Infect Immun. 1999;67:3733\u20139.","journal-title":"Infect Immun"},{"issue":"2","key":"360_CR71","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1128\/IAI.60.2.435-442.1992","volume":"60","author":"RG Russell","year":"1992","unstructured":"Russell RG, Tall BD, Morris JG Jr. Non-O1 Vibrio cholerae intestinal pathology and invasion in the removable intestinal tie adult rabbit diarrhea model. Infect Immun. 1992;60(2):435\u201342 PubMed - NCBI. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1730473. Accessed 18 May 2018.","journal-title":"Infect Immun"},{"key":"360_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.mimet.2007.08.009","volume":"71","author":"JS Yang","year":"2007","unstructured":"Yang JS, Kim HJ, Yun C-H, et al. A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses. J Microbiol Methods. 2007;71:141\u20136. https:\/\/doi.org\/10.1016\/j.mimet.2007.08.009.","journal-title":"J Microbiol Methods"},{"key":"360_CR73","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s12275-017-7478-0","volume":"55","author":"KW Kim","year":"2017","unstructured":"Kim KW, Jeong S, Ahn KB, et al. Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines. J Microbiol. 2017;55:973\u20138. https:\/\/doi.org\/10.1007\/s12275-017-7478-0.","journal-title":"J Microbiol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-020-00360-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-020-00360-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-020-00360-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T23:10:33Z","timestamp":1621897833000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-020-00360-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1186\/s12865-020-00360-1","relation":{},"ISSN":["1471-2172"],"issn-type":[{"type":"electronic","value":"1471-2172"}],"subject":[],"published":{"date-parts":[[2020,5,25]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the Animal Research Review Panel guidelines of AIMST University Human and Animal Ethics Committee (Ref No. AUHAEC\/FAS\/2015\/02) and the Animal Ethics Committee (AEC) (Ref No. USM\/IACUC\/2017 (833)), USM.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}